Compare Invesco Ltd. (IVZ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Invesco Ltd. trades at $27.87 (market cap $12.77B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.97% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IVZ | SYRE | |
|---|---|---|
Market Cap | $12.77B | $7.52B |
Volume | 2,758,656 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $33.31 | $108.92 |
52-Week Low | $22.44 | $22.18 |
Typical Hold Time | 77 Days | 0 Days |
Enterprise Value | $22.93B | $6.52B |
Dividend Yield | 2.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $27.93, down 4.55% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, with a negative net income margin of -0.93%. Recent news highlights product expansions, including the launch of the Invesco Nasdaq International Innovators 100 ETF, and a dividend of $0.22 per share scheduled for September 2026.
The outlook is cautious; analyst consensus is a buy with a $33.17 price target, but profitability challenges and bearish technicals pose risks. Positive cash flow and AUM growth offer potential, yet investors must weigh weak margins against strategic initiatives in a competitive ETF landscape.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
